X4 Pharmaceuticals (NASDAQ:XFOR) Raised to “Strong-Buy” at Wells Fargo & Company

X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by research analysts at Wells Fargo & Company to a “strong-buy” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.70.

X4 Pharmaceuticals Stock Up 11.4%

Shares of NASDAQ:XFOR opened at $4.41 on Friday. The business has a 50-day moving average price of $4.07 and a 200 day moving average price of $3.95. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $415.95 million, a price-to-earnings ratio of -0.97 and a beta of 0.35. X4 Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The firm had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million. Sell-side analysts expect that X4 Pharmaceuticals will post -0.77 EPS for the current year.

Insiders Place Their Bets

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the period. Rhumbline Advisers grew its stake in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares in the last quarter. Jane Street Group LLC grew its stake in shares of X4 Pharmaceuticals by 112.5% in the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after acquiring an additional 51,544 shares in the last quarter. Vanguard Group Inc. increased its position in shares of X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after acquiring an additional 178,593 shares during the period. Finally, Two Sigma Investments LP purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth $47,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.